Advertisement
Person › Details
Jörn Aldag (Hookipa Biotech AG)
Aldag, Jörn (Hookipa Biotech 201606– CEO before Uniqure/AMT + Evotec + MAN GHH)
Organisation | Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT) | |
Today | Uniqure N.V. (Nasdaq: QURE) | |
Product | vaccine technology | |
Product 2 | gene therapy | |
Record changed: 2024-02-06 |
Advertisement
More documents for Jörn Aldag
- [1] Genespire S.r.l.. (7/30/20). "Press Release: Genespire Appoints Jörn Aldag as Chairman of the Board of Directors". Milan....
- [2] Hookipa Biotech AG. (2/6/18). "Press Release: Hookipa Biotech to Attend the Leerink Partners 7th Annual Global Healthcare Conference". Vienna....
- [3] Hookipa Biotech AG. (12/21/17). "Press Release: Hookipa Biotech to Present at 36th Annual J.P. Morgan Healthcare Conference 2018". Vienna....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top